Therapeutic Area: Other Immune Biology

Final Analysis of Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in the CANDOR Study.

Usmani SZ, et al.
Blood Advances
May 2023
Authors and Affiliates
Saad Z. Usmani,1 Hang Quach,2 Maria-Victoria Mateos,3 Ola Landgren,4 Xavier Leleu,5 David Siegel,6 Katja Weisel,7 Xiaomei Shu,8 Chuang Li,9 Meletios Dimopoulos10 1Memorial Sloan Kettering Cancer Center, New York, NY, United States of America; 2University of Melbourne, St Vincent’s Hospital, Melbourne, VIC, Australia; 3University Hospital Salamanca/ISAI, Salamanca, Spain; 4Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States of America; 5CHU de Poitiers – La Miletrie/INSERM CIC 1402, Poitiers, France; 6John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, United States of America; 7University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 8Paraxel, Chengdu, China; 9Amgen Inc., Thousand Oaks, CA, United States of America; 10National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Martin T, et al.
Blood Cancer Journal
May 2023
Authors and Affiliates
Thomas Martin 1,22, Meletios-Athanasios Dimopoulos 2, Joseph Mikhael 3, Kwee Yong 4, Marcelo Capra5, Thierry Facon6,Roman Hajek 7, Ivan Špička8, Ross Baker9, Kihyun Kim10, Gracia Martinez11, Chang-Ki Min12, Ludek Pour13, Xavier Leleu 14, Albert Oriol 15, Youngil Koh16, Kenshi Suzuki17, France Casca18, Sandrine Macé19, Marie-Laure Risse20 and Philippe Moreau21,22 1Department of Hematology, University of California at San Francisco, San Francisco, CA, USA. 2The National and Kapodistrian University of Athens, Athens, Greece. 3Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 4Department of Haematology, University College Hospital, London, UK. 5Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil. 6Department of Haematology, Lille University Hospital, Lille, France. 7Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. 8Department of Hematology, 1st Faculty of Medicine, Charles University andGeneral Hospital, Prague, Czech Republic. 9Perth Blood Institute, Murdoch University, Perth, Australia. 10Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 11Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo,Brazil. 12Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea. 13Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. 14Service d’Hématologie et Thérapie Cellulaire, CHU and CIC Inserm, 1402 Poitiers Cedex, France. 15Institut Josep Carreras and Institut Catala d’Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain. 16Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. 17Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan. 18Ividata Life Science, Levallois-Perret, France. 19Sanofi, R&D, Chilly-Mazarin, France. 20Sanofi, R&D, Vitry-sur-Seine, France. 21Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France. 22These authors contributed equally: Thomas Martin, PhilippeMoreau

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.

Frigault MJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Matthew J. Frigault,1,2 Michael R. Bishop,3 Jacalyn Rosenblatt,4 Elizabeth K. O’Donnell,1,2 Noopur Raje,1,2 Daniella Cook,1,2 Andrew J. Yee,1,2 Emma Logan,4 David E. Avigan,4 Andrzej Jakubowiak,3 Kit Shaw,5 Heather Daley,5 Sarah Nikiforow,5 Faith Griffin,6 Christine Cornwell,6 Angela Shen,6 Christopher Heery,6 and Marcela V. Maus1,2 1Massachusetts General Hospital Cancer Center, Boston, MA; 2Harvard Medical School, Boston, MA; 3David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL; 4Beth Israel Deaconess Medical Center, Boston, MA; 5Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA; and 6Arcellx, Inc., Gaithersburg, MD

Perturbations of the T-cell immune repertoire in kidney transplant rejection

Sigdel TK, et al.
April 2023
immuneAccess
Authors and Affiliates
Tara K Sigdel 1, Paul A Fields 2, Juliane Liberto 1, Izabella Damm 1, Maggie Kerwin 1, Jill Hood 2, Parhom Towfighi 1, Marina Sirota 1, Harlan S Robins 2, Minnie M Sarwal 1; 1 Department of Surgery, Division of Multi Organ Transplantation, University of California, San Francisco, San Francisco, CA, United States. 2 Adaptive Biotechnologies, Seattle, WA, United States.

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.

Fonseca R, et al.
Blood Cancer Journal
March 2023
Authors and Affiliates
Rodrigo Fonseca 1, Mariano Arribas 1, Julia E. Wiedmeier-Nutor1, Yael N. Kusne1, Miguel González Vélez2, Heidi E. Kosiorek3, Richard (Duke) J. Butterfield3, Ilan R. Kirsch4, Joseph R. Mikhael 5, A. Keith Stewart6, Craig Reeder 1, Jeremy Larsen1, P. Leif Bergsagel 1 and Rafael Fonseca 1 1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 2Dignity Health Cancer Institute, Phoenix, AZ, USA. 3Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. 4Translational Medicine, Adaptive Biotechnologies, Seattle, WA, USA. 5Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 6Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.

Urushihara R, et al.
eJHaem
January 2023
Authors and Affiliates
Ryota Urushihara1 Naoki Takezako3 Takeshi Yoroidaka1 Takeshi Yamashita4 Ryoichi Murata4 Kenji Satou2 Shinji Nakao1 Hiroyuki Takamatsu1,2 1Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan 2Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa, Japan 3Department of Hematology, Disaster Medical Center of Japan, Tachikawa, Japan 4Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Dytfeld D, et al.
Lancet Oncology
January 2023
Authors and Affiliates
Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter-Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Agnieszka Końska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B Lahoud, Jeffrey A Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A Derman, Andrzej J Jakubowiak Poznan University of Medical Sciences, Poznan, Poland (D Dytfeld MD PhD, T Kubicki MD, A Nowicki MD PhD, T Szczepaniak MD, A Łojko-Dankowska MD PhD, M Matuszak MD PhD, Prof L Gil MD PhD); Wroclaw Medical University, Wroclaw, Poland (Prof T Wróbel MD PhD, J Rybka MD PhD, M Majcherek MD PhD, Prof L Usnarska-Zubkiewicz MD PhD); Institute of Hematology and Blood Transfusion, Warsaw, Poland (Prof K Jamroziak MD PhD, B Puła MD PhD, A Końska MD);Medical University of Lodz, Lodz, Poland (P Robak MD PhD, D Mikulski MD, Prof T Robak MD PhD); Medical University of Lublin, Lublin, Poland (A Walter-Croneck MD PhD, O Czabak MD PhD); Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland (J Czyż MD PhD, L Szukalski MD); Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland (A Tyczyńska MD, Prof J M Zaucha MD PhD); Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (A Druzd-Sitek MD PhD, Prof J Walewski MD PhD);Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland (Prof K Giannopoulos MD PhD);Memorial Sloan-Kettering Cancer Institute, New York, NY, USA (O B Lahoud MD);Karmanos Cancer Institute, Detroit, MI, USA(J A Zonder MD); University of Michigan, Ann Arbor, MI, USA(K Griffith MS); University of Chicago Medical Center, Chicago, IL, USA (A Stefka MS, A Major MD, B A Derman MD, Prof A J Jakubowiak PhD);University of Colorado School of Medicine, Aurora, CO, USA (A Major)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

Cohen AD, et al.
Blood
January 2023
Authors and Affiliates
Adam D. Cohen,1 María-Victoria Mateos,2 Yael C. Cohen,3 Paula Rodriguez-Otero,4 Bruno Paiva,4 Niels W.C.J. van de Donk,5 Thomas Martin,6 Attaya Suvannasankha,7 Kevin C. De Braganca,8 Christina Corsale,8 Jordan M. Schecter,8 Helen Varsos,8 William Deraedt,9 Liwei Wang,8 Martin Vogel,10 Tito Roccia,10 Xiaoying Xu,8 Pankaj Mistry,11 Enrique Zudaire,12 Muhammad Akram,13 Tonia Nesheiwat,13 Lida Pacaud,13 Irit Avivi,3 and Jesus San-Miguel4 1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; 2Hospital Clinico Universitario de Salamanca, Salamanca, Spain; 3Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 4Clinica Universidad de Navarra, CCUN, Centro de Investigación, Medica Aplicada (CIMA), Instituto de Investigación, Sanitaria de Navarra (IDISNA, CIBERONC), CIBER-ONC CB16/12/00369, Pamplona, Spain; 5Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; 6UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 7Indiana University Simon Cancer Center, Indiana University and Roudebush VAMC, Indianapolis, IN; 8Janssen R&D, Raritan, NJ; 9Janssen R&D, Beerse, Belgium; 10Janssen Global Services, LLC, Raritan, NJ; 11Janssen R&D, High Wycombe, United Kingdom; 12Janssen R&D, Springhouse, PA; and 13Legend Biotech USA, Piscataway, NJ

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.

Ramchandren R, et al.
The Lancet
December 2022
Authors and Affiliates
Radhakrishnan Ramchandren,a Peter Johnson,b Nilanjan Ghosh,c Jia Ruan,d Kirit M. Ardeshna,e Roderick Johnson,f Gregor Verhoef,g David Cunningham,h Sven de Vos,i Shireen Kassam,j Luis Fayad,k John Radford,l Sarah Bailly,m Fritz Offner,n David Morgan,o Javier Munoz,p,s Jerry Ping,q Edith Szafer-Glusman,q Karl Eckert,q Jutta K. Neuenburg,q and Andre Goy a Division of Hematology/Oncology, University of Tennessee Health Science Center, Knoxville, TN, USA b Cancer Research UK Clinical Centre, Southampton General Hospital, Southampton, UK c Levine Cancer Institute, Atrium Health, Charlotte, NC, USA d Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA e University College London/UCL Hospitals, Biomedical Research Centre, London, UK f Leeds Cancer Centre at St. James’s University Hospital, Leeds, UK g Department of Haematology, UZ Leuven – Campus Gasthuisberg, Leuven, Belgium h Gastrointestinal and Lymphoma Unit, The Royal Marsden NHS Foundation Trust – Royal Marsden Hospital, London, UK i Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA j Haematology Department, King’s College Hospital, London, UK k Department of Lymphoma-Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA l Division of Cancer Sciences, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UK m Cliniques Universitaires Saint-Luc, Université Catholique de Louvain Brussels, Brussels, Belgium n Department of Clinical Hematology, Universitair Ziekenhuis Gent, Ghent, Belgium o Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA p Department of Hematology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA q Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA r Department of Hematology & Oncology, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA